New pages
Jump to navigation
Jump to search
24 June 2026
- 00:5000:50, 24 June 2026 Summary and evolution of AIS Guidelines (hist | edit) [21,092 bytes] Hasnain Ali (talk | contribs) (Created page with "__NOTOC__ {{Ischemic stroke}} {{CMG}}{{AE}} {{HAM}} ==Summary Evolution of AHA/ASA Stroke Guidelines: 2018<ref name="pmid29367334">{{cite journal| author=Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K | display-authors=etal| title=2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. | journal=Stroke | year= 201...")
23 June 2026
- 23:3123:31, 23 June 2026 Sandbox:HAM (hist | edit) [91,906 bytes] Hasnain Ali (talk | contribs) (Created page with "== 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association == === DIAGNOSTIC EVALUATION FOR SECONDARY STROKE PREVENTION === {| class="wikitable" style="width:80%" |- | colspan="1" style="text-align:center; background:LightGreen" |Class I |- | bgcolor="LightGreen" |'''1.'...")
16 June 2026
- 14:3214:32, 16 June 2026 Sebetralstat (hist | edit) [22,454 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=plasma kallikrein inhibitor |indicationType=treatment |indication=acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. |adverseReactions=headache(incidence ≥2%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult=====FDA-labeled Indi...")
12 June 2026
- 12:4112:41, 12 June 2026 Linvoseltamab-gcpt (hist | edit) [33,540 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=linvoseltamab |aOrAn=a |drugClass=bispecific B-cell maturation antigen (BCMA)‑directed CD3 T-cell engager |indicationType=treatment |indication=adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. |hasBlackBoxWarning=Yes...")
11 June 2026
- 12:2412:24, 11 June 2026 Garadacimab-gxii (hist | edit) [17,277 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=an |drugClass=activated Factor XII (FXIIa) inhibitor (monoclonal antibody) |indicationType=prophylaxis |indication=preventing attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. |adverseReactions=are nasopharyngitis and abdominal pain (incidence ≥ 7%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#F...")
10 June 2026
- 00:3500:35, 10 June 2026 Mechanical circulatory support in cardiogenic shock (hist | edit) [42,188 bytes] Nehal Eid (talk | contribs) (Created page with "### Mechanical Circulatory Support in Cardiogenic Shock **NOTOC** {{Mechanical circulatory support in cardiogenic shock}} {{CMG}}; {{AE}} {{Nehal}} ==Overview== Cardiogenic shock (CS) is a clinical syndrome of inadequate tissue perfusion due to the inability of the heart to pump sufficient blood to meet metabolic demands. Despite advances in reperfusion therapy and critical care, CS remains the leading cause of in-hospital death among patients with acute m...")
- 00:1800:18, 10 June 2026 Emergent PCI protocols and door-to-balloon time management (hist | edit) [39,839 bytes] Nehal Eid (talk | contribs) (Created page with " {{CMG}} {{AE}} {{Nehal}} NOTOC {{SI}} ==Overview== Emergent percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for patients presenting with ST-segment elevation myocardial infarction (STEMI). The concept of '''door-to-balloon (D2B) time''' refers to the interval from a patient's arrival at the hospital to the inflation of the first balloon (or activation of the first device) to restore coronary blood flow. Timely primary PCI (PPCI...")
7 June 2026
- 21:4221:42, 7 June 2026 Taletrectinib (hist | edit) [32,641 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). |adverseReactions=diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue (>20%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</...")
6 June 2026
- 22:1522:15, 6 June 2026 GC rich repressor elements (hist | edit) [757 bytes] Marshallsumter (talk | contribs) (Created page with "==GC rich repressor element== GC rich repressor element Down regulation of smooth muscle myosin heavy chain (SM MHC) expression in cultured smooth muscle cells is associated with progressive methylation of a GC rich repressor element (GCGGGA) within the SM MHC promoter.[1] ==References== 1. Julian M Rozenberg, Daniel B Tesfu, Srilaxmi Musunuri, Joan M Taylor & Christopher P Mack (December 2014). DNA methylation...")
- 19:4019:40, 6 June 2026 Α-Palindromic binding proteins (hist | edit) [1,001 bytes] Marshallsumter (talk | contribs) (Created page with "α-Palindromic binding proteins The palindromic sequence here designated Order 377 (r) TGCGCATGCGCA (c) ACGCGTACGCGT (1) (i) TGCGCATGCGCA (ci) ACGCGTACGCGT (1) also called the α-palindromic binding protein (α-PAL) that binds the nuclear respiratory factor 1 (NRF-1)[1] does not occur on either side of A1BG nor any other IDC. Number 377 Order 377 alpha palindromic binding protein (r) TGCGCATGCGCA = (i)...")
5 June 2026
- 12:5312:53, 5 June 2026 Clesrovimab-cfor (hist | edit) [21,676 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=respiratory syncytial virus (RSV) F protein-directed fusion inhibitor |indicationType=prevention |indication=RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. |adverseReactions=injection-site erythema (3.8%), injection-site swelling (2.7%) and rash (2.3%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</...")
3 June 2026
- 13:1313:13, 3 June 2026 Acoltremon (hist | edit) [10,394 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=TRPM8 thermoreceptor agonist |indicationType=treatment |indication=the signs and symptoms of dry eye disease. |adverseReactions=instillation site pain (50%). |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult=====FDA-labeled Indications==== * TRYPTYR is indicated for the...")
2 June 2026
- 14:2714:27, 2 June 2026 Telisotuzumab vedotin-tllv (hist | edit) [28,383 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |aOrAn=a |drugClass=a c-Met-directed antibody and microtubule inhibitor conjugate |indicationType=treatment |indication=adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. |adverseReactions=were perip...")
25 May 2026
- 13:3713:37, 25 May 2026 Avutometinib potassium and Defactinib hydrochloride (hist | edit) [35,103 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Avutometinib and Defactinib |aOrAn=a |drugClass=combination of avutometinib and defactinib, each kinase inhibitors, |indicationType=treatment |indication=adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. |adverseReactions=laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase...")
- 11:5511:55, 25 May 2026 Nipocalimab-aahu (hist | edit) [30,203 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=Nipocalimab |aOrAn=a |drugClass=neonatal Fc receptor blocker |indicationType=treatment |indication=generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReactions=respiratory tract infections, peripheral edema, and muscle spasms ( in patients with gMG treate...")